Overview

Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection

Status:
Completed

Trial end date:
2016-06-22

Target enrollment:

Participant gender:

Summary

The primary objectives of this study are to evaluate the efficacy, safety and tolerability of treatment with sofosbuvir/velpatasvir (SOF/VEL) for 12 weeks in participants with chronic HCV infection who were coinfected with HIV-1.

Phase:

Phase 3

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Sofosbuvir
Sofosbuvir-velpatasvir drug combination
Velpatasvir